Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 17 | 274 | 278 | 711 | 929 |
| Gross Profit | 17 | 274 | 278 | 711 | 929 |
| Operating Expenses | 43,783 | 35,774 | 30,281 | 35,308 | 29,946 |
| Operating Income | -43,766 | -35,500 | -30,003 | -34,597 | -29,017 |
| Interest Expense | 7,563 | 7,158 | 5,547 | 3,202 | 2,274 |
| Other Income | 2,413 | 1,742 | 225 | 71 | 37 |
| Pre-tax Income | -48,916 | -40,916 | -35,325 | -37,728 | -31,254 |
| Income Tax | N/A | -1 | N/A | 4 | N/A |
| Net Income Continuous | -48,916 | -40,915 | -35,325 | -37,732 | -31,254 |
| Net Income | $-48,916 | $-40,915 | $-35,325 | $-37,732 | $-31,254 |
| EPS Basic Total Ops | -1.12 | -0.95 | -0.90 | -0.97 | -0.80 |
| EPS Basic Continuous Ops | -1.12 | -0.95 | -0.90 | -0.97 | -0.80 |
| EPS Diluted Total Ops | -1.12 | -0.95 | -0.90 | -0.97 | -0.80 |
| EPS Diluted Continuous Ops | -1.12 | -0.95 | -0.90 | -0.97 | -0.80 |
| EPS Diluted Before Non-Recurring Items | -1.12 | -0.95 | -0.90 | -0.97 | N/A |
| EBITDA(a) | $-42,275 | $-33,940 | $-28,675 | $-33,629 | $-28,200 |